Bibliographic Details
| Title: |
Targeting syndecan-1: new opportunities in cancer therapy. |
| Authors: |
Zecheng Yang1,2, Shuaitong Chen1,2, Haoqiang Ying3, Wantong Yao1 wyao2@mdanderson.org |
| Source: |
American Journal of Physiology: Cell Physiology. Jul2022, Vol. 323 Issue 1, pC29-C45. 17p. |
| Subject Terms: |
*SYNDECANS, *HEPARAN sulfate proteoglycans, *CANCER treatment, *CELL morphology, *CELLULAR signal transduction |
| Abstract: |
Syndecan-1 (SDC1, CD138) is one of the heparan sulfate proteoglycans and is essential for maintaining normal cell morphology, interacting with the extracellular and intracellular protein repertoire, as well as mediating signaling transduction upon environmental stimuli. The critical role of SDC1 in promoting tumorigenesis and metastasis has been increasingly recognized in various cancer types, implying a promising potential of utilizing SDC1 as a novel target for cancer therapy. This review summarizes the current knowledge on SDC1 structure and functions, including its role in tumor biology. We also discuss the highlights and limitations of current SDC1-targeted therapies as well as the obstacles in developing new therapeutic methods, offering our perspective on the future directions to target SDC1 for cancer treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of American Journal of Physiology: Cell Physiology is the property of American Physiological Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
